Tahla Munir, MBChB, PhD, discusses the rationale for a MAIC of the phase 3 SEQUOIA and AMPLIFY trials in chronic lymphocytic leukemia.
Talha Munir, MBChB, PhD
Advertisement
Tahla Munir, MBChB, PhD, is a consultant hematologist at Leeds Teaching Hospitals NHS Trust and deputy chair of the United Kingdom National Cancer Research Institute Chronic Lymphocytic Leukemia Study Group, in Leeds, UK.
Articles by Talha Munir, MBChB, PhD
Presented by Talha Munir, MBChB, PhD, this matching-adjusted indirect comparison demonstrated a significant progression-free survival advantage for zanubrutinib over fixed-duration acalabrutinib plus venetoclax in low-risk, treatment-naive chronic lymphocytic leukemia, with a 36-month progression-free survival rate of 88.5% vs 77%, respectively.
Tahla Munir, MBChB, PhD, details the efficacy of first-line zanubrutinib and clinical implications for treatment selection in CLL.
An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5